{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:58:51Z","timestamp":1793289531332,"version":"4.5.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway, typically triggered by a \u201ctwo-hit\u201d mechanism. It is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage, most commonly affecting the kidneys. While our understanding of the complement system has advanced significantly, CM-HUS remains a complex, heterogeneous disorder influenced by a spectrum of genetic variants, risk haplotypes, and acquired factors such as anti-factor H autoantibodies. This review highlights the current knowledge of CM-HUS pathogenesis, focusing on genetic variants in regulatory and activating proteins of the complement system. We also discuss the diagnostic complexity posed by incomplete penetrance, overlapping phenotypes, and limitations of genetic and functional assays. Emerging ex-vivo assays and complement biomarkers are explored as tools for refining diagnosis and risk stratification. The use of complement inhibitors such as eculizumab and ravulizumab has significantly improved renal outcomes and survival. This review provides a comprehensive, clinically grounded update on the genetics, pathophysiology, diagnostics, and therapeutic considerations in CM-HUS, aiming to provide clinicians and researchers with a deeper understanding of this complex, complement-driven disease.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1621317","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:47:21Z","timestamp":1768376841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Complement-mediated HUS revisited: evolving insights into pathophysiology, diagnosis, and treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruah","family":"Alyamany","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M","family":"Moyer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice V.","family":"Willrich","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Sridharan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: A systematic literature review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2018.07.006","article-title":"Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management","volume":"461","author":"Sridharan","year":"2018","journal-title":"J Immunol Methods"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.clim.2023.109828","article-title":"Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management","volume":"257","author":"Cole","year":"2023","journal-title":"Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.56.082103.104540","article-title":"Definition and clinical importance of haplotypes","volume":"56","author":"Crawford","year":"2005","journal-title":"Annu Rev Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B9","volume-title":"Genetic Atypical Hemolytic-Uremic Syndrome","author":"Noris","year":"1993"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","article-title":"Alternative complement pathway assessment in patients with atypical HUS","volume":"365","author":"Roumenina","year":"2011","journal-title":"J Immunol Methods"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914496","article-title":"Underlying genetics of aHUS: which connection with outcome and treatment discontinuation","volume":"24","author":"Spasiano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"831044","DOI":"10.3389\/fimmu.2021.831044","article-title":"Editorial: function and dysfunction of complement factor H","volume":"12","author":"Jozsi","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03552.x","article-title":"Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H","volume":"151","author":"de Cordoba","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002903200","article-title":"Each of the three binding sites on complement factor H interacts with a distinct site on C3b","volume":"275","author":"Jokiranta","year":"2000","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Martin Merinero","year":"2021","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16651","article-title":"Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome","volume":"111","author":"Manuelian","year":"2003","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005080868","article-title":"Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions","volume":"17","author":"Jozsi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1681\/ASN.V122297","article-title":"The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20","volume":"12","author":"Caprioli","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660194","article-title":"A family affair: addressing the challenges of factor H and the related proteins","volume":"12","author":"Poppelaars","year":"2021","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1011580","article-title":"CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome","volume":"13","author":"Piras","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ng1890","article-title":"A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration","volume":"38","author":"Hughes","year":"2006","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PloS Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1371\/journal.pmed.0030431","article-title":"Atypical haemolytic uraemic syndrome associated with a hybrid complement gene","volume":"3","author":"Venables","year":"2006","journal-title":"PloS Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(95)00116-6","article-title":"cDNA cloning, sequencing and chromosomal assignment of the gene for mouse complement factor I (C3b\/C4b inactivator): identification of a species specific divergent segment in factor I","volume":"33","author":"Minta","year":"1996","journal-title":"Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1994.1585","article-title":"The organization of the human complement factor I gene (IF): a member of the serine protease gene family","volume":"24","author":"Vyse","year":"1994","journal-title":"Genomics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.12.021","article-title":"Hot spot of complement factor I rare variant p.Ile357Met in patients with hemolytic uremic syndrome","volume":"84","author":"Schwotzer","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939280","article-title":"Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I","volume":"40","author":"Nilsson","year":"2010","journal-title":"Eur J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005101051","article-title":"Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome","volume":"17","author":"Fremeaux-Bacchi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb05998.x","article-title":"Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues","volume":"94","author":"Endoh","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.07.004","article-title":"Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome","volume":"44","author":"Richards","year":"2007","journal-title":"Mol Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713041","article-title":"The rationale of complement blockade of the MCP(ggaac) haplotype following atypical hemolytic uremic syndrome of three Southeastern European countries with a literature review","volume":"24","author":"Turudic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006931","article-title":"Familial risk of developing atypical hemolytic-uremic syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.03.248","article-title":"The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome","volume":"66","author":"Martinez-Barricarte","year":"2015","journal-title":"Mol Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.608604","article-title":"A novel homozygous in-frame deletion in complement factor 3 underlies early-onset autosomal recessive atypical hemolytic uremic syndrome - case report","volume":"12","author":"Pollack","year":"2021","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.06.041","article-title":"Does complement factor B have a role in the pathogenesis of atypical HUS","volume":"43","author":"Kavanagh","year":"2006","journal-title":"Mol Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-023-05939-5","article-title":"Clinical features and outcomes of patients with diacylglycerol kinase epsilon nephropathy: a nationwide experience","volume":"38","author":"Khandelwal","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2021-3","article-title":"No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome","volume":"104","author":"Miyata","year":"2016","journal-title":"Int J Hematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.07.020","article-title":"On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome","volume":"104","author":"Huerta","year":"2023","journal-title":"Kidney Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome","volume":"141","author":"Fakhouri","year":"2023","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.tru.2020.100002","article-title":"Challenges in classification of novel CFH variants in patients with atypical hemolytic uremic syndrome","volume":"1","author":"Sridharan","year":"2020","journal-title":"Thromb Update"},{"key":"B56","doi-asserted-by":"publisher","first-page":"107452","DOI":"10.1016\/j.jbc.2024.107452","article-title":"Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort","volume":"300","author":"Hallam","year":"2024","journal-title":"J Biol Chem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602284","article-title":"Functional characterization of rare genetic variants in the N-terminus of complement factor H in aHUS, C3G, and AMD","volume":"11","author":"Wong","year":"2020","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.789897","article-title":"Functional analysis of variants in complement factor I identified in age-related macular degeneration and atypical hemolytic uremic syndrome","volume":"12","author":"de Jong","year":"2021","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931210","article-title":"Anti-factor H antibody and its role in atypical hemolytic uremic syndrome","volume":"13","author":"Raina","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: A nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.07.008","article-title":"Diagnostic utility of complement serology for atypical hemolytic uremic syndrome","volume":"93","author":"Sridharan","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-071472","article-title":"Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome","volume":"110","author":"Jozsi","year":"2007","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00853","article-title":"Rare functional variants in complement genes and anti-FH autoantibodies-associated aHUS","volume":"10","author":"Valoti","year":"2019","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05390-4","article-title":"Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection","volume":"37","author":"Khandelwal","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp166","article-title":"Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases","volume":"24","author":"Kwon","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05750611","article-title":"Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8949-2_15","article-title":"Anti-factor H autoantibodies assay by ELISA","volume":"1901","author":"Senant","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-724-2_20","article-title":"Anti-factor H autoantibodies assay","volume":"1100","author":"Dragon-Durey","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06374-w","article-title":"Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus","volume":"39","author":"Khandelwal","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1527016","DOI":"10.3389\/fimmu.2024.1527016","article-title":"Novel immunochromatographic test for rapid detection of anti-factor H autoantibodies with an assessment of its clinical relevance","volume":"15","author":"Rodriguez de Cordoba","year":"2024","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05451-2","article-title":"Systematic review of atypical hemolytic uremic syndrome biomarkers","volume":"37","author":"Raina","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","article-title":"The impact of eculizumab on routine complement assays","volume":"460","author":"Willrich","year":"2018","journal-title":"J Immunol Methods"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.04.022","article-title":"Ex vivo C5b-9 deposition test to monitor complement activity in clinical and subclinical atypical hemolytic uremic syndrome and in transplantation-associated thrombotic microangiopathy","volume":"9","author":"Martin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"108616","DOI":"10.1016\/j.clim.2020.108616","article-title":"Ex vivo assays to detect complement activation in complementopathies","volume":"221","author":"Yuan","year":"2020","journal-title":"Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.5414\/CN110516","article-title":"Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data","volume":"97","author":"Tomazos","year":"2022","journal-title":"Clin Nephrol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2948-7","article-title":"Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome","volume":"30","author":"Khandelwal","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814389","article-title":"Immunosuppressive therapy of antibody-mediated aHUS and TTP","volume":"24","author":"Kelen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.028","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"92","author":"Brocklebank","year":"2017","journal-title":"Kidney Int"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transpl"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005135","article-title":"Kidney transplantation in patients with aHUS: A comparison of eculizumab prophylaxis versus rescue therapy","volume":"109","author":"Duineveld","year":"2025","journal-title":"Transplantation"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02212-3","article-title":"Using large-scale population-based data to improve disease risk assessment of clinical variants","volume":"57","author":"Forrest","year":"2025","journal-title":"Nat Genet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40246-022-00407-x","article-title":"Expanding ACMG variant classification guidelines into a general framework","volume":"16","author":"Masson","year":"2022","journal-title":"Hum Genomics"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-021-00903-z","article-title":"Stepwise ABC system for classification of any type of genetic variant","volume":"30","author":"Houge","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B94","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","article-title":"Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation","volume":"7","author":"Acosta-Medina","year":"2023","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:54Z","timestamp":1771911594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2025.1621317"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1621317","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1621317"}}